What Conditions Is Psilocybin-Assisted Therapy Currently Approved to Treat in Australia?
Psilocybin-assisted therapy (PAT) has emerged as a significant development in Australian mental health care. Since July 1, 2023, the Therapeutic Goods Administration (TGA) has permitted the prescribing of psilocybin for a specific, narrowly defined condition. This makes Australia the first national regulator to recognise psilocybin as a medicine within a formal healthcare framework. Nevertheless, the approval is not a general licence for mental health treatment. Consequently, understanding which conditions are currently approved, and which are not, is essential for anyone considering this innovative therapy.
The Only Approved Indication: Treatment-Resistant Depression
Currently, the sole condition for which psilocybin-assisted therapy is legally approved in Australia is treatment-resistant depression (TRD) . For this specific use, psilocybin is a Schedule 8 (Controlled Drug) medicine. For all other indications, it remains a Schedule 9 (Prohibited Substance).
What Does Treatment-Resistant Depression Mean?
Treatment-resistant depression is not a specific diagnosis but a clinical classification. It generally refers to major depressive disorder (MDD) that has not responded adequately to at least two different courses of antidepressant treatment. The definition typically includes:
- Failure of multiple treatments: Patients must have tried and not responded to at least two different classes of antidepressants.
- Sufficient dosage and duration: The treatment courses must have been at therapeutic doses for an adequate period (e.g., at least 6 weeks).
- Documentation: A clear history of treatment failure is essential.
It is important to note that the definition of TRD is evolving, and different clinicians may use slightly different criteria. For instance, some researchers define TRD as a lack of response to 2 or more antidepressant trials, while others may require more. As one expert noted, “not all treatment failures are created equal,” and a diagnosis of TRD often requires “not just one medication, but quite a few”. The TGA guidance emphasizes that psychiatrists must consider all other approved treatment options before prescribing psilocybin, ensuring it is truly a last-line option for severe cases.
The Role of the Psychiatrist in Determining Eligibility
The eligibility for PAT is not a simple checklist. Ultimately, an authorised psychiatrist makes the clinical decision. Only psychiatrists registered with the Medical Board of Australia and who are Fellows of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) can prescribe psilocybin. They are responsible for:
- Assessing the patient’s history: Thoroughly reviewing the patient’s psychiatric history and treatment response.
- Confirming TRD: Determining if the patient truly meets the criteria for treatment-resistant depression.
- Ensuring other treatments have been exhausted: Verifying that all TGA-approved treatments have been considered and trialled.
- Obtaining informed consent: Ensuring the patient fully understands the risks and benefits of PAT.
- Overseeing the therapy: The psychiatrist must remain present during the therapy session.
What Is Not Approved for Psilocybin Therapy
It is crucial to understand the limitations of the current approval. Psilocybin is not legally approved for any of the following conditions in Australia:
- Generalised anxiety disorder (GAD)
- Post-traumatic stress disorder (PTSD)
- Depression without resistance
- Chronic pain conditions
- Obsessive-compulsive disorder (OCD)
- Alcohol or substance use disorders
- Terminal illness-related anxiety
While clinical research into these and other conditions is ongoing, they remain outside the scope of the current approval. The approval is specifically for TRD and does not extend to any other mental health condition.
How the Approved Use Differs from Clinical Research
It is important to distinguish between the legal approval for clinical use and ongoing research. A substantial amount of clinical research is being conducted in Australia on other potential applications of psilocybin. These operate under a different regulatory framework.
Examples of Australian Clinical Trials:
- Generalised Anxiety Disorder: A world-first trial at Monash University is testing psilocybin-assisted therapy for primary anxiety disorder.
- PTSD: Monash University is conducting a trial examining MDMA-assisted psychotherapy for PTSD in veterans and first responders.
- Depression and Anxiety in Palliative Care: St Vincent’s Hospital Melbourne has completed trials for patients with life-threatening illnesses.
- Post-Concussion Symptoms: Monash University has launched Australia’s first clinical trial testing psilocybin for persistent post-concussion symptoms.
Participation in these trials requires meeting specific inclusion criteria. They are not a substitute for the approved medical pathway for TRD.
The Authorised Prescriber Pathway
The TGA’s Authorised Prescriber (AP) scheme is the mechanism through which psilocybin is available for TRD. A 2024 study confirmed that the scheme is being used for TRD, with patients and psychiatrists willing to treat severe TRD reporting high levels of satisfaction.
- Referral: A patient with suspected TRD receives a referral to a psychiatrist who is or can become an Authorised Prescriber.
- Assessment: The psychiatrist confirms the diagnosis and reviews all previous treatments.
- Protocol Development: The psychiatrist develops a clinical treatment protocol, which must receive approval from a registered Human Research Ethics Committee (HREC).
- TGA Authorisation: The psychiatrist applies to the TGA for specific authorisation to prescribe psilocybin.
- Treatment: The patient undergoes a course of psychedelic-assisted psychotherapy in a medically supervised setting.
Conclusion
Psilocybin-assisted therapy is currently approved in Australia exclusively for the treatment of treatment-resistant depression. This is a tightly controlled, last-line therapy available only through authorised psychiatrists. It is not approved for any other mental health or medical condition. For patients with TRD who have exhausted other options, this represents a new and potentially life-changing treatment. For those with other conditions, the only legal avenue for psilocybin is participation in a clinical trial. This guide is for educational and research purposes only and does not constitute legal advice. If you believe you may be eligible for PAT, the first step is to discuss your situation with a General Practitioner. They can refer you to a suitably qualified psychiatrist.be eligible for PAT, the first step is to discuss your situation with a General Practitioner, who can refer you to a suitably qualified psychiatrist.